Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Evaluate Escalating Doses of SGX201 [Delayed Release Oral Beclomethasone Dipropionate (BDP)] for Prevention of Signs and Symptoms of Acute Enteritis in Patients With Rectal Cancer Treated With Combined Chemotherapy and Radiation Therapy

NCT01073384 is registered in ClinicalTrials.gov with Soligenix as lead sponsor.

NCT NCT01073384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01073384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Evaluate Escalating Doses of SGX201 [Delayed Release Oral Beclomethasone Dipropionate (BDP)] for Prevention of Signs and Symptoms of Acute Enteritis in Patients With Rectal Cancer Treated With Combined Chemotherapy and Radiation Therapy
Lead sponsor
Soligenix
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2009
Completion date
November 30, 2012
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

enteritis